Short answer
SWK Holdings Corp (SWKH) filed its fiscal 2024 10-K annual report with the SEC on Mar 20, 2025. It reported revenue of $4M (+200.8% year over year) and net income of $13M.
- Top risk flagged: Regulatory risk: LIBOR transition impacted by the Adjustable Interest Rate (LIBOR) Act of 2022, with synthetic U.S. dollar LIBOR continuing until September 2024
FY2024 key financial metrics · XBRL
- Revenue
- $4M
- +200.8% YoY
- Net income
- $13M
- −15.1% YoY
- Operating margin
- 320.4%
- −898.4 pp YoY
- EPS (diluted)
- $1.08
- −13.6% YoY
- ROE
- 4.7%
- −1.0 pp YoY
- Operating cash flow
- $23M
- +54.8% YoY
Source: XBRL data from the SWK Holdings Corp (SWKH) FY2024 10-K on SEC EDGAR. USD.
SWK Holdings Corp FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: dual segments of specialty finance in life sciences and pharmaceutical development/manufacturing
- Pharmaceutical Development segment entered asset sale process with March 2024 exclusive option to sell Enteris BioPharma assets by January 2026, classified as held for sale as of Dec 31, 2024
- Focus on sub-$50 million finance transactions niche, with $852.5 million funded across 58 deals since strategy inception, mitigating competition from larger players
- Finance Receivables fund transactions up to $25 million fully via own capital, syndicating larger deals; no current investment advisory partnerships despite previous collaborations
- Strategic shift toward potential exit from pharmaceutical manufacturing business, emphasizing finance receivables and asset-light life science capital solutions
Management Discussion & Analysis
- Revenue $45.0M, up $7.2M YoY; Finance Receivables $4.8M increase, Pharmaceutical Development $2.4M increase
- Net income $13.5M, down $2.4M YoY; interest expense rose to $4.7M from $1.8M; provision for credit losses increased to $12.8M
- Best segment: Finance Receivables revenue up $4.8M; worst: $5.8M intangible assets impairment in 2024, goodwill impairment $8.4M in 2023
- Cash $5.9M, up $1.4M; capital allocation includes $6.0M share repurchases, $64.1M investment funding, $6.2M net credit facility payment
- Management highlights $277.8M finance receivables portfolio; expects positive 2025 cash flows; risk from floating interest rates and borrower repayments
Risk Factors
- Regulatory risk: LIBOR transition impacted by the Adjustable Interest Rate (LIBOR) Act of 2022, with synthetic U.S. dollar LIBOR continuing until September 2024
- Macroeconomic risk: Silicon Valley Bank closure by California Department of Financial Protection and Innovation on March 10, 2023, impacting financial services liquidity
- Supply chain vulnerability: Life science partner companies face risks from limited suppliers of components and potential manufacturing disruptions
- Competitive risk: Increasing competition from hedge funds entering royalty and debt-backed investment markets, intensifying pressure on opportunity sourcing
- Financial risk: Concentration risk due to limited number of significant assets, increasing exposure to individual partner company underperformance or credit losses
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.